Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evolution of Pulse Pressure Following Initiation of Antihypertensive Therapy in Patients With Essential Arterial Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02202525
Recruitment Status : Completed
First Posted : July 29, 2014
Last Update Posted : July 29, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
The main purpose of this prospective, multicentre, french observational study is to analyse the evolution of pulse pressure (PP) and to identify its prognostic factors in hypertensive patients three months after initiation of a new hypertensive therapy. The PP is defined as the difference between systolic blood pressure (SBP) and diastolic blood pressure (DBP).

Condition or disease Intervention/treatment
Hypertension Drug: Micardis® Drug: Other hypertensives

Layout table for study information
Study Type : Observational
Actual Enrollment : 2148 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evolution of Pulse Pressure Following Initiation of Antihypertensive Therapy
Study Start Date : January 2001
Actual Primary Completion Date : March 2002

Resource links provided by the National Library of Medicine

Drug Information available for: Telmisartan

Group/Cohort Intervention/treatment
Essential arterial hypertension
Patients with essential arterial hypertension needing a new antihypertensive therapy
Drug: Micardis®
Other Name: Telmisartan

Drug: Other hypertensives



Primary Outcome Measures :
  1. Changes from baseline in pulse pressure [ Time Frame: Up to 3 months after start of treatment ]
  2. Number of patients with adverse drug reactions [ Time Frame: Up to 3 months after start of treatment ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with essential hypertenstion treated by private or hospital cardiologists
Criteria

Inclusion Criteria:

  • Patients with essential arterial hypertension needing a new antihypertensive therapy
  • A patient was included by the physician only if he/she had agreed after being informed about the study

Exclusion Criteria:

Additional Information:
Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02202525    
Other Study ID Numbers: 502.362
First Posted: July 29, 2014    Key Record Dates
Last Update Posted: July 29, 2014
Last Verified: July 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Vascular Diseases
Cardiovascular Diseases
Telmisartan
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action